• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [25363 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Basque Office for Health Technology Assessment (OSTEBA) [Effectiveness and safety of bone suppression technology for the detection of lung cancer and indications for its use]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Technology Assessment programme PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
2018     Basque Office for Health Technology Assessment (OSTEBA) [Strategies for promoting and strengthening evidence-based nursing in the Basque Country]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Search for guidelines for the update of the DMP "coronary heart disease"]
2018     Belgian Health Care Knowledge Centre (KCE) MammaPrint® test for personalised management of adjuvant chemotherapy decisions in early breast cancer
2018     Basque Office for Health Technology Assessment (OSTEBA) [Checklist for ethical and legal domains analysis]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Phlebotonics for venous insufficiency]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenegermin (moderate or severe neurotrophic keratitis) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial receptivity array in assisted reproduction]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Addendum to Commission A17-45]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders - Addendum to Commission E17-08]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [High altitude simulation test for patients with lung disease]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency percutaneous nucleoplasty in disc disorders]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Addendum to A17-50]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Thioridazine for the treatment of behavior disorders in patients with intellectual disability]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide combined with dexamethasone in multiple myeloma]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetoscopic laser photocoagulation in twin-twin transfusion syndrome]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Daratumumab for relapsed or refractory multiple myeloma]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     NIHR Health Services and Delivery Research programme Understanding new models of integrated care in developed countries: a systematic review
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Rotigotine for Parkinson’s disease]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the systematic treatment of parodontopathies]
2018     NIHR Health Technology Assessment programme Surveillance following endovascular aortic aneurysm
2018     NIHR Health Services and Delivery Research programme A staff training intervention to improve communication between people living with dementia and health-care professionals in hospital: the VOICE mixed-methods development and evaluation study
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Phototherapy and systemic treatment for moderate to severe psoriasis]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Atezolizumab in non-small cell lung cancer]
2018     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Best practices to reduce medication administration errors (MAEs) in hospital centre (HC) and long term care facilities centre (LTCF)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     NIHR Health Technology Assessment programme Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT
2018     NIHR Health Technology Assessment programme (REBALANCE) REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ramucirumab for advanced gastric or gastroesophageal junction cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Services and Delivery Research programme From programme theory to logic models for multi-specialty community providers: a realist evidence synthesis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal strategies for the diagnosis of acute pulmonary embolism: a health technology assessment
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56]
2018     NIHR Health Services and Delivery Research programme Supporting shared decision making for older people with multiple health and social care needs: a realist synthesis to inform emerging models of health and social care
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Lacosamide in epilepsy]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Composite resin versus amalgam for dental restorations: a health technology assessment
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in adult patients with dystonia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Addendum to Commission A17-58]
2018     Health Information and Quality Authority (HIQA) Guidelines for evaluating the clinical effectiveness of health technologies in Ireland
2018     NIHR Health Technology Assessment programme Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Uvulopalatopharyngoplasty for snoring and obstructive sleep apnea]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Drugs for the management of rheumatoid arthritis: clinical evaluation
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "osteoporosis" - rapid report]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extended adjuvant endocrine therapy in breast cancer]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Metastatic melanoma gap analysis
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging for focal liver lesion assessment]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018     NIHR Health Technology Assessment programme MRI versus laparoscopy to diagnose the main causes of chronic pelvic pain in women: a test-accuracy study and economic evaluation
2018     NIHR Health Technology Assessment programme Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Nabiximols for spasticity and chronic pain]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening for chlamydia trachomatis and neisseria gonorrhoeae during pregnancy: a health technology assessment
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal shock wave therapy in musculoskeletal disorders]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical evaluation of interventions for the management of insomnia: a review of reviews
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the application of fluoride varnish on milk teeth to prevent the development and progression of initial caries or new carious lesions - rapid report]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic testing in primary dystonia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab vedotin (cutaneous T-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     NIHR Health Technology Assessment programme What works to increase attendance for diabetic retinopathy screening? An evidence synthesis and economic analysis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Prompt therapy in patients with speech disorders]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Allogeneic T cells (high-risk haematological malignancies) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     NIHR Health Technology Assessment programme A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: antibiotic prophylaxis during clean orthopedic surgery in children and adults]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Global postural re-education (RPG®) in spine conditions]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Technology Assessment programme Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Gait laboratory in patients with gait disorders]
2018     Canary Health Service [Safety, effectiveness, and cost-effectiveness of subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01]
2018     NIHR Health Technology Assessment programme Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study
2018     NIHR Health Technology Assessment programme Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study
2018     NIHR Health Technology Assessment programme Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Riluzole in amyotrophic lateral sclerosis]
2018     Canary Health Service [Cost-effectiveness of vaccination against herpes zoster]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - second Addendum to Commission H16-02C]
2018     Center for Drug Evaluation (CDE) [HTA for molecular adsorbent recirculating system (MARS)]
2018     NIHR Health Technology Assessment programme Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT)
2018     NIHR Health Technology Assessment programme Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab in multiple sclerosis]
2018     Canary Health Service [Nutritional treatment of adults with chronic kidney disease (CKD) and irreversible severe energy-protein malnutrition using ordinary food]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Technology Assessment programme Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions for temporomandibular joint disorder: an overview of systematic reviews
2018     Canary Health Service [Epidermal growth factor for the treatment of diabetic foot ulcers]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults